Idiopathic Hypersomnia Clinical Trial
Official title:
A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors
Verified date | November 2017 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The term 'hypersomnia' describes a group of symptoms that includes severe daytime sleepiness
and sleeping long periods of time (more than 10 hours per night). Sometimes, hypersomnia is
caused by a problem with the quality of sleep occurring at night, for instance when nighttime
sleep is disrupted by frequent breathing pauses. In other cases, however, hypersomnia occurs
even when nighttime sleep is of good quality. These cases of hypersomnia are presumed to be a
symptom of brain dysfunction, and so are referred to as hypersomnias of central (i.e., brain)
origin, or primary hypersomnias.
The causes of most of these primary hypersomnias are not known. However, our group has
recently identified a problem with the major brain chemical responsible for sedation, known
as GABA. In a subset of our hypersomnia patients, there is a naturally-occurring substance
that causes the GABA receptor to be hyperactive. In essence, it is as though these patients
are chronically medicated with Valium (or Xanax or alcohol, all substances that act through
the GABA system), even though they do not take these medications.
Current treatment of central hypersomnias is limited. For the fraction of cases with
narcolepsy, there are FDA-approved, available treatments. However, for the remainder of
patients, there are no treatments approved by the FDA. They are usually treated with
medications approved for narcolepsy, but sleep experts agree that these medications are often
not effective for this group of patients.
Based on our understanding of the GABA abnormality in these patients, we evaluated whether
flumazenil (an medication approved by the FDA for the treatment of overdose of GABA
medications or the reversal of GABA-based anesthesia) would reverse the GABA abnormality in
our patients. In a test tube model of this disease, flumazenil does in fact return the
function of the GABA system to normal. The investigators have treated a few patients with
flumazenil and most have felt that their hypersomnia symptoms improved with this treatment.
To determine whether flumazenil is truly beneficial for primary hypersomnia, this study will
compare flumazenil to an inactive pill (the placebo). All subjects will receive both
flumazenil and the placebo at different times, and their reaction times and symptoms will be
compared on these two treatments to determine if one is superior. Currently, flumazenil can
only be given through an injection into a vein (i.e., intravenously). This study will
evaluate this intravenous dosing as well as a new form of flumazenil, which is taken as a
lozenge to be dissolved under the tongue. If this study shows that flumazenil is more
effective than placebo in the treatment of hypersomnia, it will identify a potential new
therapy for this difficult-to-treat disorder.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Hypersomnia (meeting clinical criteria for idiopathic hypersomnia with or without long sleep time, narcolepsy lacking cataplexy, or symptomatic hypersomnia not meeting International Classification of Sleep Disorders 2 (ICSD-2) criteria inclusive of habitually long sleep periods of > 10 hours/day) - evidence for GABA-related abnormality, as demonstrated by our in-house, in vitro assay - age > 18 - high performance liquid chromatography/liquid chromatography tandem mass spectrometry verification of the absence of exogenous benzodiazepines (BZDs). Exclusion Criteria: - Contraindications to use of flumazenil (pregnancy, hepatic impairment, seizure history, pre-menstrual dysphoric disorder, traumatic brain injury, cardiac disease (left ventricular diastolic dysfunction), or cardiac dysrrhythmia. - Current use of a BZD or BZD-receptor agonists - moderate or severe sleep apnea (RDI > 15/hr), severe periodic limb movement disorder (PLMI > 30/hr) - diagnosis of narcolepsy with cataplexy, as determined by ICSD-2 criteria and confirmed by absence of cerebrospinal fluid (CSF) hypocretin - metabolic disorders such as severe anemia, adrenal insufficiency, severe iron deficiency, vitamin B12 deficiency, or hypothyroidism that may explain symptoms of hypersomnia |
Country | Name | City | State |
---|---|---|---|
United States | Emory Sleep Center | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Lynn Marie Trotti | Georgia Research Alliance |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Psychomotor Vigilance Task (PVT) Median Reaction Time | The PVT measures the reaction time to button press following the presentation of a visual stimulus, reported here as the median reaction time for multiple presentations during the 10 minute task. The measure used was the change in median reaction time from baseline to drug administration, where the median reaction time at each of the time points (below) was averaged to provide a single on-treatment value for median reaction time. The measure was then calculated as baseline value - treatment value, such that higher numbers denote improvement from baseline. | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | PVT Additional Measure #1, Change in Lapse Frequency | A PVT lapse is defined as a reaction time exceeding 500 msec following the presentation of a single stimulus, which are then summed for the entire 10 minute PVT testing period. The measure used was the change in the frequency of lapses from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | PVT Additional Measure #2, Change in Duration of Lapse Domain | The PVT duration of lapse domain is defined as the reciprocal of the reaction time averaged across the slowest 10% of responses. The measure used was the change in duration of lapse domain from baseline to drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | PVT Additional Measure #3, Change in Optimum Response Times | The optimum response times is defined as the reciprocal of the reaction time averaged across the fastest 10% of responses. The measure used was the change in optimum response time from baseline to following drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | PVT Additional Measure #4, Change in False Response Frequency | The false response frequency is defined as the number of button presses when no stimulus is presented. The measure used was the change in false response frequency from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT | At the end of the 10 minute PVT testing period, subjects were asked to rate their current level of sleepiness along a line, which was transformed into a numeric value from 1-10, such that high levels indicated more severe subjective sleepiness. The measure used was the change in this rating from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | Change in Stanford Sleepiness Scale | The Stanford Sleepiness Scale (SSS) is a subjective rating of sleepiness, with score ranging from 1 to 7, where higher values reflect more severe sleepiness. The measure used was change in SSS from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) | |
Secondary | Electroencephalogram (EEG) Power | EEG signals reflect the state of excitability of the cerebral cortex and correlate highly with levels of behavioral arousal. This is quantifiable as 'power' of the signal (microvolts squared/signal frequency). The EEG signals will be acquired and stored for off-line power analysis and comparison between treatment conditions. | following drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04026958 -
Clarithromycin Mechanisms in Hypersomnia Syndromes
|
Phase 2 | |
Completed |
NCT02512588 -
A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
|
Phase 2 | |
Completed |
NCT03597555 -
Sodium Oxybate in Idiopathic Hypersomnia
|
Phase 2/Phase 3 | |
Completed |
NCT03356938 -
The Role of the Circadian System in Neurological Sleep-wake Disorders
|
N/A | |
Completed |
NCT03533114 -
A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension
|
Phase 3 | |
Active, not recruiting |
NCT03542851 -
A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia
|
Phase 2 | |
Completed |
NCT05156047 -
A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia
|
Phase 3 | |
Enrolling by invitation |
NCT05371483 -
Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
|
||
Not yet recruiting |
NCT06252571 -
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
|
Phase 2 | |
Completed |
NCT04827329 -
Anesthetic Management of Patients With Chronic Sleep Disorders
|
||
Not yet recruiting |
NCT06457945 -
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions
|
N/A | |
Recruiting |
NCT05875974 -
Ph4 PSG Combined JZP258-407
|
Phase 4 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Completed |
NCT01146600 -
Clarithromycin for the Treatment of Hypersomnia
|
Phase 2 | |
Recruiting |
NCT04330963 -
International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
|
||
Completed |
NCT04091438 -
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
|
Phase 1 | |
Recruiting |
NCT05615584 -
Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence
|
N/A | |
Recruiting |
NCT05837091 -
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
|
Phase 4 | |
Recruiting |
NCT05321355 -
Mainz Register of Patients With Sleep Disorders
|
||
Active, not recruiting |
NCT05668754 -
Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH
|
Phase 2 |